Algert Global LLC Allogene Therapeutics, Inc. Transaction History

Algert Global LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.23 - $4.38 $33,021 - $64,859	14,808 New	14,808 $35,000
Q3 2022 Nov 15, 2022	SELL	$10.32 - $17.28 $273,655 - $458,213	-26,517 Reduced 66.89%	13,125 $142,000
Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $685,254 - $1.24 Million	-101,070 Reduced 71.83%	39,642 $452,000
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $1.08 Million - $2.15 Million	140,712 New	140,712 $1.28 Million
Q4 2021 Feb 14, 2022	SELL	$13.13 - $24.52 $121,189 - $226,319	-9,230 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $193,922 - $255,117	9,230 New	9,230 $237,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.